From: Predicting treatment outcome in classical Hodgkin lymphoma: genomic advances
Histology | Incidence (%) | Age at diagnosis | Clinical characteristics | Treatment | Outcome, PFS (%) |
---|---|---|---|---|---|
cHL | 95 | Bimodal | Â | Â | Â |
   NSCHL | 70 | Young adults (10 to 30 years) | Frequent mediastinal involvement | ABVD±RT | 80 |
   MCCHL | 10 to 25 | Bimodal distribution, 3rd to 7th decade | Infrequent mediastinal involvement | ABVD±RT | <80 |
   LDCHL | 1 | Bimodal distribution, 3rd to 7th decade | Infrequent mediastinal involvement | ABVD±RT | <80 |
   LRCHL | 1 | Bimodal distribution, 3rd to 7th decade | Infrequent mediastinal involvement | ABVD±RT | >90 |
NLPHL | 5 | 4th decade | Infrequent mediastinal involvement | ABVD±RT, rituximab | Good prognosis, multiple relapses |